Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Volitionrx (VNRX) EBIT (2019 - 2025)

Volitionrx (VNRX) has disclosed EBIT for 9 consecutive years, with -$5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 13.08% year-over-year to -$5.1 million, compared with a TTM value of -$22.7 million through Sep 2025, up 24.29%, and an annual FY2024 reading of -$27.0 million, up 24.9% over the prior year.
  • EBIT was -$5.1 million for Q3 2025 at Volitionrx, up from -$6.3 million in the prior quarter.
  • Across five years, EBIT topped out at -$5.1 million in Q3 2025 and bottomed at -$9.5 million in Q2 2023.
  • Average EBIT over 5 years is -$7.4 million, with a median of -$7.7 million recorded in 2022.
  • The sharpest move saw EBIT tumbled 67.89% in 2021, then skyrocketed 34.14% in 2025.
  • Year by year, EBIT stood at -$8.8 million in 2021, then rose by 8.81% to -$8.0 million in 2022, then decreased by 9.11% to -$8.7 million in 2023, then soared by 33.86% to -$5.8 million in 2024, then grew by 11.77% to -$5.1 million in 2025.
  • Business Quant data shows EBIT for VNRX at -$5.1 million in Q3 2025, -$6.3 million in Q2 2025, and -$5.5 million in Q1 2025.